Hyperion Therapeutics Inc announces IPO
(Edit this deal
||Apr 13, 2012
PRESS RELEASE - Hyperion Therapeutics Inc sets IPO
Hyperion Therapeutics Inc. filed to raise up to $57.5 million in an initial public offering, with plans to use proceeds for drug development and other corporate purposes.
The biopharmaceutical company, which focuses on treatments for orphan diseases and conditions of the liver, is developing a drug to treat urea cycle disorders, rare genetic diseases marked by an individual's inability to naturally manage ammonia levels in their body.
The drug, Ravicti, is being reviewed by the U.S. Food and Drug Administration.
The company, which had no revenue last year, posted a wider loss in 2011 over the year earlier.
The company has applied to list on the Nasdaq Global Market under the symbol HPTX.